Bellerophon Announces $3.0 Million Registered Direct Offering

WARREN, N.J., May 10, 2017 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into a definitive agreement with a single institutional investor for an offering of shares of its common stock with gross proceeds of $3.0 million in a registered direct offering. The closing of the offering is expected to take place on or about May 15, 2017, subject to the satisfaction of customary closing conditions.